



(11) **EP 2 090 577 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A3)
Corrections, see
Bibliography INID code(s) 22

(51) Int Cl.:
C07D 471/04 ^(2006.01) **C07D 487/04** ^(2006.01)
C07D 498/04 ^(2006.01) **A61K 31/4985** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:
11.02.2015 Bulletin 2015/07

(88) Date of publication A3:
26.08.2009 Bulletin 2009/35

(43) Date of publication A2:
19.08.2009 Bulletin 2009/34

(21) Application number: **09006829.7**

(22) Date of filing: **18.10.2007**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**
Designated Extension States:
AL BA HR MK RS

(30) Priority: **19.10.2006 US 853166 P**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
07861467.4 / 2 078 016

(71) Applicant: **Signal Pharmaceuticals, LLC**
San Diego, CA 92121 (US)

(72) Inventors:
• **Mortensen, Deborah Sue**
San Diego
CA 92117 (US)
• **Mederos, Maria Mercedes Delgado**
San Diego
CA 92126 (US)
• **Sapienza, John Joseph**
Chula Vista
CA 91913 (US)
• **Albers, Ronald J.**
San Diego
CA 92111 (US)
• **Lee, Brandon G**
Encinitas, CA 92024 (US)
• **Harris, Roy Leonard III**
San Diego
CA 92109 (US)


- **Shevlin, Graziella Isabel**
San Diego
CA 92129 (US)
- **Huang, Dehua**
San Diego
CA 92130 (US)
- **Schwarz, Kimberley Lyn**
San Diego
CA 92117 (US)
- **Packard, Garrick K.**
San Diego
CA 92121 (US)
- **Parnes, Jason Simon**
San Diego
CA 92130 (US)
- **Papa, Patrick William**
Carlsbad
CA 92008 (US)
- **Tehrani, Lida Radnia**
San Diego
CA 92131 (US)
- **Perrin-Ninkovic, Sophie**
Carlsbad
CA 92010 (US)
- **Riggs, Jennifer R.**
Cardiff
CA 92007 (US)

(74) Representative: **Savic, Bojan et al**
Jones Day
Rechtsanwälte Attorneys-at-Law Patentanwälte
Prinzregentenstraße 11
80538 München (DE)

(54) **Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors**

EP 2 090 577 A8

(57) Provided herein are Heteroaryl Compounds having the following structure:



(I)

wherein R¹, R², L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.